Philips and Illumina partner up for integrated genomics oncology solution

pharmafile | January 11, 2017 | News story | Research and Development Illumina, Philips, oncology 

Technology firm Philips and biotech Illumina have announced they are to partner up in collaboration which plans to marry the latter’s genetic sequencing and BaseSpace Sequence Hub tech with the former’s IntelliSpace Genomics cloud-based clinical informatics platform in a bid to pursue and commercialise new oncology R&D solutions.

The treatment of cancer increasingly calls for the use of genomic data and DNA sequencing to profile tumours and identify mutations, but only a small number of the hundreds of gene variants within a cancer patients present actionable therapeutic opportunities; Philips and Illumina’s new solution aims to tackle this problem by providing a rapid and accurate method to interpret genomic findings.

The partnership plans to operate by utilising Illumina’s sequencing platform to harvest and consolidate data from sources including radiology, digital pathology and immunohistochemistry, as well as medical records and laboratory tests, which will then be processed by Philips’ clinical informatics tech to provide useful and applicable insights.

The duo stated that they will be looking to partner with US health systems to aid the development of precision medicine solutions in oncology, in addition to system integration, cohort analysis and health economics applications, with the hope that this new offering will help users “develop insights more efficiently and will ultimately support lowering the cost of healthcare delivery and improved health outcomes.”

“The value of genomic information for personalized care, and for the treatment of patients with cancer in particular, is tremendous,” said Jeroen Tas, CEO of Connected Care and Health Informatics at Philips. “Until now the ability to use genomic data with the aim of having a precise diagnosis of cancer and improve treatment was mostly for the domain of academic centres. Through this collaboration we will unlock the value of genomics for a much wider group of laboratories and care providers to help them advance genomics initiatives at greater speed with the aim to offer precision medicine with better outcomes for their patients.”

Illumina president and CEO Francis deSouza added: “We believe that this collaboration will provide an excellent path for our next-generation sequencing systems to be incorporated into health systems in the U.S. and worldwide. One key strategy in our commitment to improving human health is connecting genomics to the everyday business of healthcare: based on integrated patient data, embedded into clinical pathways, supported by real-world evidence and reimbursement models.”

Matt Fellows

Related Content

Sunbird Bio and Glympse Bio merge for development of protein-based diagnostic technology

Sunbird Bio has announced that it has completed a merger with Glympse Bio, intending to …

BioIVT acquires PrecisionMed for neurology and oncology research

BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological …


UK nonprofit National Cancer Research Institute to close

The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years …

Latest content